Letònia - letó - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Letònia - letó - Zāļu valsts aģentūra

sandoz d.d., slovenia - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Unió Europea - letó - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriāze - imūnsupresanti - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Unió Europea - letó - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Unió Europea - letó - EMA (European Medicines Agency)

mylan ireland limited - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unió Europea - letó - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Letònia - letó - Zāļu valsts aģentūra

sandoz d.d., slovenia - dimetilfumarāts - zarnās šķīstošā kapsula, cietā - 120 mg

Letònia - letó - Zāļu valsts aģentūra

sandoz d.d., slovenia - dimetilfumarāts - zarnās šķīstošā kapsula, cietā - 240 mg

Unió Europea - letó - EMA (European Medicines Agency)

teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Letònia - letó - Zāļu valsts aģentūra

stada arzneimittel ag, germany - dimetilfumarāts - zarnās šķīstošā kapsula, cietā - 120 mg